Our study presented here suggests that the Wee1 inhibitor MK-1775 may act by destabilizing the attachment between kinetochores and microtubules, and could serve as a basis for improving and developing Wee1-targeted cancer chemotherapy. The gene discussed is WEE1; the disease is cancer.